Clinical summary of ACPA literature in early and established rheumatoid arthritis. Clinical summary of ACPA literature in early and established rheumatoid.

Slides:

Advertisements

Similar presentations

RHEUMATOID ARTHRITIS MUHAMMAD ADEEL (BIOT 412) Human Diseases Presentation.

Advertisements

Autoantibodies from single circulating plasmablasts react with citrullinated antigens and Porphyromonas gingivalis in rheumatoid arthritis Kaihong Su,

BIOMARKERS TO GUIDE TREATMENT IN RA

Consultant Rheumatologist

ARTHRITIS Rheumatoid Arthritis Presented By: Ali Raza Ansar Qudsia Sehar Hafsa Kabir Rheumatoid Arthritis Presented By: Ali Raza Ansar Qudsia Sehar Hafsa.

Recommendation 4: Antibody Testing in Patients with UPIA.

Autoantibodies associated with Rheumatic disease

Recommendation 1: Defining & Diagnosing UPIA. Learning Objectives State the definition of Undifferentiated Peripheral Inflammatory Arthritis (UPIA) Describe.

Rheumatoid Factor (RF)

Type II Collagen Autoimmunity in Rheumatoid Arthritis

Rheumatoid arthritis The Lancet

Figure 2. Series of surveillance bone scans

Rheumatoid Factor (RF)

Prediction of Response to Targeted Treatment in Rheumatoid Arthritis

NETosis is not a source of cellular hypercitrullination.

RESULTS INTRODUCTION METHODS CONCLUSIONS ACKNOWLEDGMENTS

Figure 3 Example of how a noncoding regulatory rheumatoid

Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on rheumatoid arthritis (RA) management. Algorithm based on the.

Figure 2 A timeline summarizing the development of diagnostic tools in rheumatology Figure 2 | A timeline summarizing the development of diagnostic tools.

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 2 Assays for detecting antidrug antibodies to TNF inhibitors

Figure 3 Proposed mechanisms underlying the links

Multivariable model of abatacept retention in biologic-naïve patients.

Receiver operating characteristic (ROC) curves: rapid radiographic progression prognosis by anticyclic citrullinated peptides generation 2 antibodies (anti-CCP2),

Mean change from baseline in disease and disability outcomes at 6 months for abatacept initiators by anti-CCP status. Mean change from baseline in disease.

Mean change in patient-reported outcomes from baseline to Week 25 with biweekly or monthly pegloticase compared with placebo. Mean change in patient-reported.

Figure 1 Location of HLA variants known to be associated

Is RA Treatment Addressing the Real Needs of Patients?

Multivariable model of abatacept retention by RF and anti-CCP status in biologic-naïve patients with or without radiographic erosion at baseline. Multivariable.

(A) EULAR response based on DAS28 (ESR, otherwise CRP) and (B) Boolean remission, at 6 months in patients treated with abatacept as a first-line biologic.

Rheumatoid Arthritis 2015 Guidelines What's New? What's Different?

ACR20, ACR50, and ACR70 response rates during the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. ACR20,

Minyoung Her, MD, Arthur Kavanaugh, MD

Figure 2 Overlap of associated loci among five rheumatic diseases

Figure 2 Interaction effects between heterozygous HLA‑DRB1

Nat. Rev. Rheumatol. doi: /nrrheum

Work arrangements, productivity, and self-confidence at work as affected by RA. a For example: Stopped working altogether, moved from full-time to part-time.

Association between anti-CCP antibody status and response to remission, LDA and mACR by anti-CCP status and TNFi initiators (multivariable models). Association.

Nat. Rev. Rheumatol. doi: /nrrheum

Intro: Biomarkers in RA

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Overview of biosimilar product development

Conversion to ACPA and RF seronegative status in patients with early RA treated with abatacept+MTX compared with MTX alone. Conversion to ACPA and RF seronegative.

Clinical and serological evolution of the presented case.

Cells and mediators of the immune-inflammatory ‘cascade’ leading to overt clinical rheumatoid arthritis are described. Cells and mediators of the immune-inflammatory.

Mean change from baseline CDAI in abatacept and TNFi initiators with a typical patient profile. Mean change from baseline CDAI in abatacept and TNFi initiators.

Mean change from baseline in disease and disability outcomes at 6 months for TNFi initiators by anti-CCP status. Mean change from baseline in disease and.

Calprotectin levels in children with enthesis-related arthritis (ERA), arthritis controls (oligoarticular and polyarticular juvenile idiopathic arthritis),

Mean differences with 95% CI between the Internal Family Systems (IFS) intervention group and the education group in study outcomes at baseline and 3,

Microbial Molecules from the Multitudes within Us

Fig. 1 Anti-LtxA antibody concentrations in various patient groups.

Additional efficacy outcomes for the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. Additional efficacy.

Carmelo Carmona-Rivera et al. Sci. Immunol. 2018;3:eaar3701

IL-6-dependent changes in preclinical phase of arthritis in gp130F759.

The earliest pathological changes of arthritis in gp130F759 develop at 5 months of age. The earliest pathological changes of arthritis in gp130F759 develop.

Clinical paradigms and pathogenetic explanations.

Cox proportional-hazards model of time to first RA flare after treatment withdrawal for patients who entered the re-treatment period (n=146). Cox proportional-hazards.

Least squares mean changes from baseline (and 95% CIs) at month three for (A) HAQ-DI, (B) FACIT-F and (C) SF-36 physical functioning domain observed in.

Percentage of patients achieving 20% improvement in the American College of Rheumatology criteria at week 12 by patient demographic and disease characteristics.

Malignancy-related events over time for all-bari-RA analysis set (IR).

The proportions (and 95% CIs) of anti-CCP+/RF+, anti-CCP+/RF- anti-CCP-/RF+ and anti-CCP-/RF- patients receiving tofacitinib 5 or 10 mg two times a day.

The proportions (and 95% CIs) of anti-CCP+/RF+, anti-CCP+/RF-, anti-CCP-/RF+ and anti-CCP-/RF- patients receiving tofacitinib 5 or 10 mg two times a day.

Joint pain location and severity.

(A–F) Changes of B-cell numbers and B-cell related biomarkers.

ACPA and RF titres in patients with early RA treated with abatacept+MTX compared with MTX alone. ACPA and RF titres in patients with early RA treated with.

Percentage of patients achieving remission by conversion to ACPA seronegative status. Percentage of patients achieving remission by conversion to ACPA.

Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on rheumatoid arthritis (RA) management. Algorithm based on the.

Anti-CarALB antibody prevalence and levels in RA and other CTD

a. a. 35–47 mediate the binding of mCRP to CFH in ELISAs

Fig. 1 Anti-LtxA antibody concentrations in various patient groups.

Presentation transcript:

Clinical summary of ACPA literature in early and established rheumatoid arthritis. Clinical summary of ACPA literature in early and established rheumatoid arthritis. Anti-Sa ELISA (Euroimmun): anticitrullinated vimentin (target is an in vitro citrullinated native protein); anti-CCP ELISA (several companies): anticyclic citrullinated peptide (target is an in vitro synthetic peptide); anti-MCV ELISA (Orgentec): anti-mutated citrullinated vimentin (target is a multi-mutated recombinant vimentin molecule made in Escherichia coli and secondarily citrullinated in vitro). RF: rheumatoid factor. HENRI A. MÉNARD J Rheumatol 2015;42:733-735 ©2015 by The Journal of Rheumatology